# Xarelto [SPAF] Post-marketing Surveillance in Japan

> **NCT01582737** · — · COMPLETED · sponsor: **Bayer** · enrollment: 11310 (actual)

## Conditions studied

- Brain Ischemia

## Interventions

- **DRUG:** Rivaroxaban(Xarelto, BAY59-7939)

## Key facts

- **NCT ID:** NCT01582737
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-30
- **Primary completion:** 2019-03-31
- **Final completion:** 2020-01-17
- **Target enrollment:** 11310 (ACTUAL)
- **Last updated:** 2023-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01582737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01582737, "Xarelto [SPAF] Post-marketing Surveillance in Japan". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01582737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*